NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION. // Digital Chinese Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S146532492601025X?dgcid=rss_sd_all
NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION. Digital Chinese Medicine. https://www.sciencedirect.com/science/article/pii/S146532492601025X?dgcid=rss_sd_all
“NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION.” Digital Chinese Medicine.
@article{article5278,
title = {NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION},
journal = {Digital Chinese Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S146532492601025X?dgcid=rss_sd_all}
}
Publication date: January 2027 Source: Cytotherapy, Volume 29, Issue 1 Author(s): Matic Bartol, Tina Fink, Tina Tragin, Ema Pleško, Roman Jerala, Hana Esih, Aljaž Kravanja, Brina Štante, Valentina Bianco, Luka Fajs, Mojca Jež